A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer

X. Cynthia(Washington University in St. Louis), Matthew J. Ellis(Guardant (United States)), Ian S. Hagemann(Washington University in St. Louis), Matthew P. Goetz(Mayo Clinic), Charles L. Loprinzi(Mayo Clinic in Arizona), Lee G. Wilke(University of Wisconsin–Madison), Jeremy Hoog(Washington University in St. Louis), Erica K. Barnell(Washington University in St. Louis), Charles Erlichman(Roswell Park Comprehensive Cancer Center), Hussam Al‐Kateb(Washington University in St. Louis), Tufia C. Haddad(Mayo Clinic), Malachi Griffith(Washington University in St. Louis), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Donald W. Northfelt(Mayo Clinic in Arizona), Zachary L. Skidmore(James S. McDonnell Foundation), Mark E. Burkard(University of Wisconsin–Madison), Julie A. Margenthaler(Washington University in St. Louis), Elaine R. Mardis(Nationwide Children's Hospital), Rebecca Aft(Washington University in St. Louis), Foluso O. Ademuyiwa(Washington University in St. Louis), Leslie Nehring(Washington University in St. Louis), Timothy J. Moynihan(Mayo Clinic), Tina J. Hieken(Mayo Clinic), Kilannin Krysiak(Washington University in St. Louis), Souzan Sanati(Washington University in St. Louis), Vera J. Suman(Mayo Clinic in Arizona), Michael Naughton(Boston College), Amyé Tevaarwerk(Mayo Clinic), Yan-Yang Feng(James S. McDonnell Foundation), Richard J. Gray(Mayo Clinic), L. Austin Doyle(Ontario Institute for Cancer Research), Kiran Vij(Washington University in St. Louis), Zhanfang Guo(Washington University in St. Louis), Obi L. Griffith(Washington University in St. Louis)
Clinical Cancer Research
September 5, 2017
Cited by 74


Related Papers